Business Model: Manufacturing / OEM, B2B
Category: Biotechnology, Health Care, Medical Device, Cardiology
Geographic Markets: Europe, North America, Israel
V-Wave has developed an implantable shunt meant to treat heart failure patients by regulating left atrial pressure.
V-Wave’s team of medical scientists have designed the small shunt that can be implanted trans-venously where it shunts excess blood away from the left ventricle, a problem that leads to over 3 million hospitalizations a year. By focusing on the cause of the heart disease and not just the symptoms V-Wave is striving to create a solution that enhances the quality and length of life for patients.
V-Wave makes money by selling implantable devices for treating patients with chronic Heart Failure.
The Due Diligence Report for V-Wave, prepared with crowd analysis and predictive algorithms, perfect for investment assessment, research and general in depth analysis.
V-Wave began clinical trials in 2013 in Israel, the United States and Europe. The V-Wave shunt is currently under investigation in multiple clinical trials in North America, Europe and Israel.
A key component of V-Wave’s team are the five medical doctors on board with decades of experience in cardiology.
V-Wave’s product could potential disrupt the market by treating an increasingly widespread medical problem.
Occlutech, is a rapidly expanding European hi-tech company specializing in developing and manufacturing cardiac occlusion devices and other vascular implants.
Corvia Medical a medical device company, focuses on developing structural heart devices for the treatment of heart failure.
Confidentiality: The Elephant, the online trading arena, provides a balance between the private shareholders (employees and former employees) need to protect its confidential information and the investor’s need for the transparency necessary to make an informed investment decision.
Content Sources: All the information presented above was retrieved from public sources (media, company website, data from the registrar of private shareholder, etc.).
Responsibility: The Elephant does not accept any responsibility or liability for the accuracy, content and reliability of this information.